[Tanvex BioPharma, Inc.] Q1 2026 EPS -1.47 NTD
Key facts
- [Tanvex BioPharma, Inc.] Q1 2026 EPS -1.47 NTD
- Tanvex BioPharma reported its Q1 2026 financial results, posting an EPS of -1.47 NTD and a net loss of 389 million NTD on revenues of 133 million NTD.
- Source: PR Times
- Date: March 1, 2026
Direct answer
Tanvex BioPharma reported its Q1 2026 financial results, posting an EPS of -1.47 NTD and a net loss of 389 million NTD on revenues of 133 million NTD.
- Citation
- [Tanvex BioPharma, Inc.] Q1 2026 EPS -1.47 NTD (March 1, 2026), PR Times
- Source
- PR Times
- Date
- March 1, 2026
Tanvex BioPharma reported its Q1 2026 financial results, posting an EPS of -1.47 NTD and a net loss of 389 million NTD on revenues of 133 million NTD.
📋 Article Processing Timeline
- 📰 Published: March 1, 2026 at 09:00
- 🔍 Collected: May 16, 2026 at 08:00 (1823h 0m after Published)
- 🤖 AI Analyzed: May 16, 2026 at 08:06 (6 min after Collected)
Company Code: 6541
Company Name: Tanvex BioPharma, Inc.
Industry: Biotechnology and Medical Care
Year/Quarter: 2026 Q1
Basic Earnings Per Share: -1.47 NTD
Operating Revenue: 133 million NTD
Net Income After Tax: -389 million NTD
Company Name: Tanvex BioPharma, Inc.
Industry: Biotechnology and Medical Care
Year/Quarter: 2026 Q1
Basic Earnings Per Share: -1.47 NTD
Operating Revenue: 133 million NTD
Net Income After Tax: -389 million NTD
FAQ
What are the key facts in this article?
Tanvex BioPharma reported its Q1 2026 financial results, posting an EPS of -1.47 NTD and a net loss of 389 million NTD on revenues of 133 million NTD.
What is the direct answer?
Tanvex BioPharma reported its Q1 2026 financial results, posting an EPS of -1.47 NTD and a net loss of 389 million NTD on revenues of 133 million NTD.
What is the source and date?
PR Times: https://openapi.twse.com.tw/financial/twse-fin-6541-2026Q1 | March 1, 2026